Real-world treatment survival outcomes for zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among treatment-naïve patients with chronic lymphocytic leukemia (CLL) in the United States

A real-world comparison of treatment and survival outcomes with zanubrutinib (zanu) and acalabrutinib (acala) monotherapy among patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) in the United States

Updated safety and efficacy of all‑oral sonrotoclax + zanubrutinib in relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), including patients with del(17p)/TP53

Combination treatment with novel BCL2 inhibitor sonrotoclax (BGB-11417) and zanubrutinib in patients with relapsed/refractory mantle cell lymphoma (R/R MCL): Results from a phase 1/1b study

First-line treatment of CLL/SLL with the all-oral combination of sonrotoclax and zanubrutinib achieves undetectable minimal residual disease rates of >90%, including in patients with del(17p)/TP53

Long-term follow-up for safety and efficacy of zanubrutinib in elderly (≥80 Years) treatment‑naïve CLL/SLL patients, including those with del(17p): Subgroup analysis from the SEQUOIA trial

Subsequent therapies and time to second progression-free survival events in chronic lymphocytic leukemia/small lymphocytic lymphoma previously treated with zanubrutinib or bendamustine-rituximab

Zanubrutinib vs ibrutinib in treatment-naive chronic lymphocytic leukemia (CLL): Implications for interpreting fixed-duration treatment outcomes from CLL17

A longitudinal analysis of patients with CLL/SLL with impaired health-related quality of life scores at baseline who were treated with zanubrutinib versus ibrutinib: A post hoc analysis of ALPINE

Real-world zanubrutinib treatment patterns in CLL/SLL among US community oncology patients with prior acalabrutinib therapy